The Cambridge Biotechnology firm , Genzyme Corp had got approval to manufacture Myozyme in Europe and market it in the US.

According to a statement by Genzyme the European Commission has approved the 4,000-liter manufacturing process of Myozyme at its facility in Geel, Belgium.

Myozyme has been approveds to treat the painful Pompe disease which is fatal inherited disorder.

The drug will be made commercially available immediately.

In a separate statement, Genzyme has also declared that the Food and Drug Administration has given it permission to market Synvisc-One, a product intended for the relief of pain associated with osteoarthritis of the knee.

The FDA has approved a single-injection version of intra-articular hylan G-F 20 (Synvisc-One) for relieving osteoarthritis knee pain. The injection is a derivative of hyaluronic acid. It cures arthritis by replacing the synovial fluid that has become degraded because of osteoarthritis.

However, the shots are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee.